CLCP1, or cytosolic carboxypeptidase 1, is a protein that plays a significant role in the post-translational modification of tubulin, the main building block of microtubules in cells. By removing glutamate residues from the C-terminus of tubulin, CLCP1 is involved in the regulation of microtubule dynamics, which is critical for various cellular processes including cell division, intracellular trafficking, and cell morphology maintenance. The precise regulation of microtubule stability and structure by CLCP1 is essential for proper cellular function and adaptation to different physiological conditions. Beyond its role in tubulin processing, CLCP1 may participate in the processing of other substrates, implicating it in a broader spectrum of cellular activities, although these functions are less understood. The activity of CLCP1, therefore, contributes to the cellular architecture and dynamics, underscoring its importance in maintaining cellular integrity and response to environmental stimuli.
The activation of CLCP1 is a complex process that likely involves multiple regulatory mechanisms, ensuring that its activity is finely tuned to the cellular context and requirements. One potential mechanism for the activation of CLCP1 could involve its localization within the cell, as the accessibility to its substrates is critical for its function. Post-translational modifications, such as phosphorylation or ubiquitination, may also regulate the activity of CLCP1, either by directly modifying the enzyme itself or by altering the interaction with its substrates or with other proteins that modulate its activity. Furthermore, changes in intracellular calcium levels have been known to affect the function of various cytosolic carboxypeptidases, suggesting that calcium signaling could play a role in the activation of CLCP1. Additionally, the presence of specific co-factors or interacting proteins may be required for the optimal activity of CLCP1, highlighting the importance of protein-protein interactions in its regulation. Through these mechanisms, the activity of CLCP1 is precisely controlled, allowing for the proper regulation of microtubule dynamics and other cellular processes in which it is involved, thereby ensuring cellular adaptability and homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and may influence CLCP1 indirectly by altering microtubule dynamics, which CLCP1 is known to interact with. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization. Its impact on microtubules could indirectly affect CLCP1 functions related to cytoskeletal organization. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin and disrupts microtubule formation. This alteration of microtubule dynamics can indirectly modulate CLCP1 activities. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine inhibits microtubule formation. By altering microtubule dynamics, it might indirectly influence CLCP1 function. | ||||||
Epothilone B, Synthetic | 152044-54-7 | sc-203944 | 2 mg | $176.00 | ||
Epothilone B stabilizes microtubules and may indirectly affect CLCP1 by altering microtubule dynamics, similar to Paclitaxel. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase and increases cAMP levels, potentially influencing pathways that could indirectly modulate CLCP1 activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX increases intracellular cAMP by inhibiting phosphodiesterases, which could indirectly influence CLCP1 activity through cAMP-dependent pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that impacts actin cytoskeleton dynamics. Since CLCP1 is associated with cytoskeletal regulation, inhibiting ROCK might indirectly influence CLCP1 activity. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin inhibits myosin II, affecting cytoskeletal dynamics. This may have an indirect impact on CLCP1, which is linked to cytoskeletal organization. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments, potentially affecting CLCP1 activity indirectly by altering actin cytoskeleton dynamics. | ||||||